STVN: Q3 growth held firm, while one GLP-1 program tempers 2027 growth

What happened

Stevanato Group’s third-quarter revenue rose 8%, as growth in its BDS business offset weakness in engineering, and its adjusted EBITDA margin, meaning adjusted operating earnings as a share of revenue, expanded to 27.2%. A single customer is expected to reduce Nexa syringe volumes, tempering 2027 growth; most affected capacity is expected to be backfilled.

Confirmed

Global impact / market context

The expected syringe-volume cut could leave Stevanato with less revenue from one customer in 2027. Backfilling most capacity could limit the effect by replacing that work, but the outlook still depends on how much volume is replaced and when.

Analyst inference

The article points to different forces in Stevanato’s outlook: recent growth in BDS offset engineering weakness, while a customer-specific reduction clouds 2027 growth. The 27.2% adjusted EBITDA margin indicates improved profit per sale in the reported quarter, but does not resolve the later volume risk.

Analyst inference

What to watch

1. Track whether BDS growth continues to offset engineering weakness in later results, since those businesses moved in opposite directions in the reported third quarter. Analyst inference
2. Look for updates on how much of the reduced Nexa syringe volume is replaced, and whether the replacement arrives in time to support 2027 growth. Analyst inference
3. Compare future revenue growth and adjusted EBITDA margin with the reported 8% increase and 27.2% margin to assess whether operating performance remains firm. Analyst inference

Evidence

• Original source link unavailable